ASH 2019 Interview - Dr Collin Chin - CAR T-cell therapy in aggressive lymphomas

Dr Collin Chin – CAR T-cell therapy in aggressive lymphomas
University of Texas MD Anderson Cancer Centre, Houston, USA
ASH meeting 2019, Orlando, USA

Dr Collin Chin is a clinical haematology fellow at the University of Texas MD Anderson Cancer Centre in Houston, Texas. He spoke with Donna Gairns, National Nurse Manager from Lymphoma Australia at the American Society of Hematology (ASH) 2019 meeting in Orlando.
Dr Chin chaired one of the aggressive lymphoma sessions that looked at prospective clinical trials and CAR T-cell therapy during the meeting.

Dr Chin provided an overview of the session that discussed the outcomes of various trials that included the outcomes of CAR T-cell therapy in relapsed/refractory DLBCL.
• Studies comparing the side effect toxicities of different products
• What side effects CAR T-cell therapy delivers
• New products emerging on the market
• Possibility of delivering CAR T as an outpatient
• Bridging therapy prior to CAR T-cell therapy
• MD Anderson Cancer Centre experience in treating over 200 patients
• Clinical trials conducted at MD Anderson in CAR T-cell therapy